Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis.

Ther Clin Risk Manag · 2011 · PMC3116803 · PMID 21691586

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Although we were unable to pool BMD results, all three trials showed a clear trend toward ongoing BMD gain (or less BMD loss) in groups where bisphosphonate therapy was continued.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.